PMID- 22283759
OWN - NLM
STAT- MEDLINE
DCOM- 20121218
LR  - 20190918
IS  - 1873-4316 (Electronic)
IS  - 1389-2010 (Linking)
VI  - 13
IP  - 8
DP  - 2012 Jun
TI  - From glutamatergic dysfunction to cognitive impairment: boundaries in the 
      therapeutic of the schizophrenia.
PG  - 1543-8
AB  - Cognitive deficits are trait markers in schizophrenia and the improvement of 
      these dysfunctions has been considered as a new frontier of treatment in this 
      disease. A current model for the patophysiology of schizophrenia states that 
      N-methyl-D-aspartate receptor (NMDAR) hypofunction leads to a dysregulation of 
      gamma-amino butyric acid (GABA) fast- spiking interneurons, consequently 
      disinhibiting pyramidal glutamatergic output and disturbing signal-to-noise 
      ratio. In this way, the modulation of the glutamate activity might constitute a 
      highly promising target for future therapeutic interventions of this disease. In 
      the present review, we discuss key regulatory elements for glutamatergic 
      neurotransmission and provide new insights into their potential role in 
      developing pharmacological treatments. Also, we emphasize the role of certain 
      chemical families as potential sources of new lead compounds with affinity for 
      metabotropic glutamate receptors (mGluRs) with cognitive enhancing properties.
FAU - Gaspar, P A
AU  - Gaspar PA
AD  - Clinica Psiquiatrica Universitaria, Hospital Clinico de la Universidad de Chile, 
      Santiago, Chile. pgaspar@neuro.med.uchile.cl
FAU - Bustamante, M L
AU  - Bustamante ML
FAU - Rojo, L E
AU  - Rojo LE
FAU - Martinez, A
AU  - Martinez A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Curr Pharm Biotechnol
JT  - Current pharmaceutical biotechnology
JID - 100960530
RN  - 0 (Receptors, Glutamate)
RN  - 3KX376GY7L (Glutamic Acid)
SB  - IM
MH  - Cognition Disorders/complications/drug therapy/*physiopathology
MH  - Glutamic Acid/*physiology
MH  - Humans
MH  - Receptors, Glutamate/*physiology
MH  - Schizophrenia/complications/drug therapy/*physiopathology
EDAT- 2012/01/31 06:00
MHDA- 2012/12/19 06:00
CRDT- 2012/01/31 06:00
PHST- 2010/04/29 00:00 [received]
PHST- 2010/10/19 00:00 [revised]
PHST- 2010/11/15 00:00 [accepted]
PHST- 2012/01/31 06:00 [entrez]
PHST- 2012/01/31 06:00 [pubmed]
PHST- 2012/12/19 06:00 [medline]
AID - CPB-EPUB-20120126-011 [pii]
AID - 10.2174/138920112800784790 [doi]
PST - ppublish
SO  - Curr Pharm Biotechnol. 2012 Jun;13(8):1543-8. doi: 10.2174/138920112800784790.